elephant circus

elephant circus Why top internet sleuths say they won't help find the UnitedHealthcare CEO killerHave you ever wanted to find all your favorite NASA technology in one place? NASA stakeholders did, too! We listened to your feedback, brainstormed user-focused features, and created the most robust technology system to date. NASA’s Space Technology Mission Directorate is excited to announce the release of TechPort version 4.0 – your gateway into our technology community. NASA tuned into feedback from the public, industry, academia, and our internal audiences to make significant updates to the TechPort system. From improvements in usability, customizability, and analysis views, users will now be able to search and explore NASA’s vast portfolio of technologies more easily than ever before. “When it comes to the ever-growing advancements in space technology, we need a system that encompasses a modernized look and feel coupled with a more intuitive interface,” said Alesyn Lowry, director for Strategic Planning & Integration for STMD at NASA Headquarters in Washington. “TechPort 4.0 offers just that. As the largest and most significant update to TechPort in the past five years, users will now be able to enjoy the most accessible, user-friendly, and all-encompassing version yet.” Check out the five features of TechPort 4.0 and how they can help you research NASA’s cutting-edge technology projects and partnerships: 1. New and Improved Homepage Featuring a new look and feel, users are able to search NASA’s comprehensive system of vast technologies. Including over 18,000 current and historical NASA technologies, users will now have more access to knowledge about the agency’s technology development at the touch of their fingertips! The modernized look and feel lends itself to a more intuitive interface that upgrades technology search capabilities. 2. Advanced Search One of the most exciting features of TechPort 4.0 is the new capability to search and filter on all fields associated with technologies. This advanced filtering feature will allow users to uncover the exact information they are seeking, creating a more accessible and swifter experience for users. 3. New Grid View Expanding upon the previous view, TechPort 4.0 offers a new grid view that enables users to view even more project data all at once. This upgrade also allows a user to customize all of the fields visible in search results, tailor how the data is sorted, and filter on any visible field. This new view provides a familiar interface tailored to data analysis needs that require rapid review of multiple data facets simultaneously. 4. NASA Technology Taxonomy Recommendation (T-Rex) NASA’s Technology Taxonomy provides a structure for technology classification spanning over 350 categories. The Taxonomy is featured in TechPort, and all technologies in the system align to at least one Taxonomy area, making it easy to view technologies of interest. Technologists from various fields, including academia and nonprofits, now have the opportunity to use the T-Rex tool to automatically classify their technology according to the NASA Taxonomy. Serving as a machine learning model, TechPort will offer more organization and an easier way for users to access relevant information. 5. Funding Opportunities Now, users can get connected, too! If your TechPort research is inspiring you to think about solving an aerospace or technology challenge, TechPort 4.0 gives users easy access to relevant opportunities and information on how to apply. Launch into TechPort 4.0 to embark on your journey into our technology community. With the wide range of improvements in accessibility and customizability, explore NASA technologies like never before! Gabrielle Thaw

AP Business SummaryBrief at 4:07 p.m. ESTPenn State's polarizing QB Drew Allar puts critics on mute and keeps winning gamesIreland’s AI data centers are sucking up too much of the country’s energy

Published 5:24 pm Friday, December 6, 2024 By Data Skrive The Carolina Hurricanes (17-8-1) visit the New York Islanders (9-11-7) at UBS Arena in Elmont, New York on December 7, 2024, starting at 5:00 PM ET on ESPN+. The Hurricanes are third in the Eastern Conference (35 points), and the Islanders are 13th in the Eastern Conference (25 points). Sign up for ESPN+ today to watch 1,000+ out-of-market NHL games, ESPN+ Hockey Night & more. Watch 1,000+ out-of-market NHL games, ESPN+ Hockey Night & more streaming all season on ESPN+. Looking for NHL tickets? Head to StubHub today and see your team live. Rep your favorite players with officially licensed NHL gear. Head to Fanatics to find jerseys, shirts, hats, and much more. Get tickets for any NHL game this season at StubHub.

Autism cases on the rise, especially among young adults

Quant Trading Society Launches QTS Investor Pro, Democratizing Algorithmic Trading for Retail Investors 12-20-2024 12:22 AM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire Quant Trading Society (QTS) [ https://www.quanttradingsociety.com/ ], a pioneering quant trading company, is transforming the financial landscape for busy professionals seeking efficient investment solutions. Through its newly launched QTS Investor Pro program, the firm is making algorithmic trading-once exclusive to hedge funds-accessible to retail investors. With over two years of development and a proven track record, QTS aims to bridge the gap between traditional investment strategies and cutting-edge trading technology. "Automation can be an intimidating concept for many investors," says Moayad Sallabi, Founder of Quant Trading Society. "Our mission is to make this advanced technology approachable, reliable, and profitable for everyone, regardless of their financial background or trading experience." QTS Investor Pro offers a comprehensive and guided experience for participants, granting them access to the firm's proprietary trading algorithms. Unlike traditional strategies limited to bonds, stocks, or real estate, the QTS system operates with a unique mechanism called the Dynamic Optimization Protocol. This protocol employs rigorous criteria to determine when and how the algorithms engage with the market, minimizing risk and ensuring consistent performance. "Dynamic Optimization is a game-changer for retail investors," explains Moayad Sallabi. "It's this innovation that sets us apart from competitors and delivers the reliability that investors demand." Since its launch, the QTS Investor Pro program has garnered significant attention, attracting over 950 users. The platform boasts an impressive rating, highlighting its effectiveness and ease of use. For added reassurance, QTS offers a 30-day money-back guarantee, ensuring clients can test the platform risk-free. One satisfied user shared, "I never imagined automated trading could be this simple. It's like having a hedge fund's capabilities in my back pocket." Algorithmic trading has long been the domain of institutional investors and hedge funds. QTS's initiative marks a pivotal moment in democratizing this sophisticated tool for everyday investors. By removing the time and effort traditionally associated with trading, the platform allows users to reap the benefits of advanced market strategies while focusing on their professional lives. Quant Trading Society envisions a financial future where automation is no longer a daunting prospect but a trusted ally for investors. The QTS Investor Pro program emphasizes a market-neutral approach, empowering participants to explore diverse financial opportunities beyond conventional assets. Applications are now open for those interested in exploring this innovative platform. Licensing opportunities are available through the Quant Trading Society website at http://www.quanttradingsociety.com , and prospective users can learn more about the company's journey and expertise via their Instagram @quanttradingsociety [ https://www.instagram.com/quanttradingsociety ]. About Company: Quant Trading Society (QTS) is a leading quant trading company headquartered in Cork, Ireland. The firm specializes in making algorithmic trading accessible to retail investors, empowering them with innovative tools to achieve consistent returns. QTS is dedicated to simplifying automation and bridging the gap between traditional investments and advanced trading strategies. Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements. Media Contact Company Name: Quant Trading Society Contact Person: Moayad Sallabi Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=quant-trading-society-launches-qts-investor-pro-democratizing-algorithmic-trading-for-retail-investors ] City: Dublin Country: Ireland Website: http://www.quanttradingsociety.com This release was published on openPR.KANSAS CITY, Mo. (AP) — It took until the fourth quarter, when Kansas City was desperately trying to fend off the lowly Las Vegas Raiders, for Chiefs coach Andy Reid to finally make a drastic change to his offensive line. The Chiefs had tried Kingsley Suamataia at left tackle to start the season. When the rookie was getting beaten routinely for pressure and sacks, they switched to second-year pro Wanya Morris, who fared no better at protecting Patrick Mahomes . In the waning minutes of a 19-17 victory Friday — one that wasn't secure until Las Vegas fumbled away a chance at a winning field goal with 15 seconds left — the Chiefs slid All-Pro left guard Joe Thuney out to tackle. Mike Caliendo entered at guard. And while they didn't have much chance to work together, the move underscored what's been a season-long problem. “That was the right thing to do at the time,” Reid said afterward. “It just solidified things.” What is the solution moving forward? Well, the Chiefs signed former Pro Bowl left tackle D.J. Humphries last week, but he's been with the team for only a few days, and he's also coming off an ACL tear that sidelined him for the entire offseason. In a perfect world, Humphries would slide into the lineup in time for the Chiefs' game against the Chargers next Sunday. In a more realistic world, the Chiefs may need to make it through another week or two before he's ready to contribute, and that would mean putting Morris back into the lineup or keeping Thuney protecting Mahomes' blind side. “I would tell you it's disruptive to any offense when the quarterback is hit," Reid acknowledged, “and not able to get the ball off." Mahomes had gone 113 straight starts without being sacked five-plus times in a game; Carolina and Las Vegas have done it in consecutive weeks. And along with the sacks have been penalties on Morris and right tackle Jawaan Taylor, which have made it hard for a Kansas City offense that has had to adapt to injuries all season to consistently put together drives. “We have to make sure we clean those things up,” Reid said. “It's hard to go backwards in this league and win games.” Yet the Chiefs keep doing it. They have won an NFL-record 14 straight one-possession games, including five decided on the final play, this season. That has allowed them to piece together an 11-1 record and already clinch a postseason bye. “You're not satisfied with where we're at, even though we're winning football games,” Mahomes said. “Our goal over these last few games is to prove the team we really are going into the playoffs and play that way in the playoffs.” What’s working The passing game has started to produce — when Mahomes has time to throw — now that DeAndre Hopkins has become more ingrained in the offense. He had four catches for 90 yards against the Raiders, and his mere presence has opened things up for others, including Travis Kelce, who had seven catches for 68 yards. What needs help The Chiefs basically abandoned an unproductive running game against Las Vegas. Isiah Pacheco ran seven times for 44 yards in his return from an ankle injury, but 34 yards came on one carry. Kareem Hunt had 15 yards on his seven attempts. Stock up Two-time All-Pro defensive tackle Chris Jones had been held without a sack for seven consecutive games, but he managed to bring down Raiders quarterback Aidan O'Connell twice. That was important given how much trouble the Chiefs have had getting to the quarterback when they aren't blitzing this season. Stock down The entire Kansas City secondary has struggled for weeks, ever since cornerback Jaylen Watson was lost to a season-ending ankle injury. Nazeeh Johnson, Chamarri Conner and Bryan Cook in particular have been inconsistent in their coverage. Injuries The Chiefs made it through the Raiders game without any injuries. Key number 10 — The Chiefs have qualified for the playoffs for 10 consecutive seasons. That is the second-longest streak in NFL history behind the Patriots, who made it 11 straight years from 2009-19. Next steps The game against the Raiders on Black Friday means the Chiefs have a couple of extra days to prepare for the Chargers. The Chiefs have beaten them six straight times, including a 17-10 win on Sept. 29 in Los Angeles. ___ AP NFL: https://apnews.com/hub/nfl Dave Skretta, The Associated PressCARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc. Best trending stories from the week. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. You may occasionally receive promotions exclusive discounted subscription offers from the Roswell Daily Record. Feel free to cancel any time via the unsubscribe link in the newsletter you received. You can also control your newsletter options via your user dashboard by signing in.

Cruise into this holiday season with a non-traditional vacationNFL ends investigation into sexual assault allegations against Browns QB Deshaun Watson

SCOTTSDALE, Ariz. (AP) — Even when Penn State quarterback Drew Allar gets some praise, it's usually a backhanded compliment. They say he's a good game manager and stays within himself, or that he doesn't try to do too much. They mention he might not be flashy, but he gives the team a chance to win. And here's the thing about Penn State since Allar stepped under center: The Nittany Lions have won games. A lot of them. Sometimes that's hard to remember considering the lukewarm reception he often gets from fans. “I get it — we have a really passionate fan base and they're a huge part of our success,” Allar said Sunday at College Football Playoff quarterfinals media day. “For us, we always want to go out there every drive and end with a touchdown, so when we don't do that, there's nobody more frustrated than us.” The polarizing Allar is having a solid season by just about any standard, completing more than 68% of his passes for 3,021 yards, 21 touchdowns and seven interceptions while leading the sixth-seeded Nittany Lions to a 12-2 record and a spot in the Fiesta Bowl for Tuesday's game against No. 3 seed Boise State. But in a college football world filled with high-scoring, explosive offenses, Allar's no-frills performances often are the object of ire. The Penn State offense is a run-first bunch , led by the talented combo of Nicholas Singleton and Kaytron Allen. “If we had a nickel for every time there was a Monday morning quarterback saying some BS stuff, we'd all be pretty rich,” offensive coordinator Andy Kotelnicki said. “I think part of being a quarterback, especially at Penn State but really anywhere, is how you respond to and manage criticism.” The 20-year-old Allar has made strides in that department after a trying 2023 season that finished with a 10-3 record. He says that's largely because once fall camp started back in August, he logged off the social media platform X. Allar said negative online experiences wore on him last year, and his phone number was leaked a few times, which added to the stress. He finally realized that controlling outside narratives was impossible, so the best course of action was to eliminate a needless distraction. “I’ve been more mentally free, as much as that sounds crazy,” Allar said. “I think that’s been a huge difference for me this year.” The biggest criticism of Allar — and really Penn State as a whole during the 11-year James Franklin era — is that he isn't capable of winning the big games. He's 0-2 against rival Ohio State and threw a late interception against Oregon in the Big Ten title game earlier this month, which sealed the Ducks' 45-37 victory . He wasn't great in the CFP's first round, either, completing just 13 of 22 passes for 127 yards as Penn State muscled past SMU 38-10 on a cold, blustery day to advance to the Fiesta Bowl. But the quarterback is confident a better performance — aided by a game that will be played in comfortable temperatures in a domed stadium — is coming. “For me, I just have to execute those (easy) throws early in the game and get our guys into rhythm,” Allar said. “Get them involved early as much as I can and that allows us to stay on the field longer, call more plays and open up our offense more. That will help us a ton, building the momentum throughout the game.” Allar might be a favorite punching bag for a section of the Penn State fan base, but that's not the case in his own locker room. Star tight end Tyler Warren praised his quarterback's ability to avoid sacks, saying that the 6-foot-5, 238-pounder brings a toughness that resonates with teammates. “He’s a football player,” Warren said. “He plays quarterback, but when you watch him play and the energy he brings and the way he runs the ball, he’s just a football player and that fires up our offense.” Now Allar and Penn State have a chance to silence critics who say that the Nittany Lions don't show up in big games. Not that he's worried about what other people think. “I think it's a skill at the end of the day — blocking out the outside noise," Allar said. "Focusing on you and the process and being honest with yourself, both good and bad.” Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football

Pure BRILLIANCE: Justice Alito Just WRECKED the Trans Civil Rights ArgumentWith Trump on the way, advocates look to states to pick up medical debt fight